Mechanisms behind the synergistic effect of sirolimus and imatinib in preventing restenosis after intimal injury

Journal of Vascular Research

Volumn 46, Issue 3, 2009, Pages 240-252

  Tigerstedt, Nina Maria ^a   Aavik, Einari ^a   Lehti, Satu ^a   Hayry, Pekka ^a   Savolainen Peltonen, Hanna ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Imatinib mesylate; Intimal hyperplasia; Restenosis; Sirolimus; Smooth muscle cells

Indexed keywords

CYSTEINE; DRUG VEHICLE; GLYCINE; GLYCINE RICH PROTEIN 2; IMATINIB; MESSENGER RNA; PROTEIN BCL 2; RAPAMYCIN; TRANSGELIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA INJURY; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; BLOOD VESSEL; BLOOD VESSEL INJURY; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL EVALUATION; CONTROLLED STUDY; DISSECTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERANCE; EX VIVO STUDY; GENE EXPRESSION; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; INTIMA; LEUKOCYTOSIS; LOADING DRUG DOSE; LONG TERM CARE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; RESTENOSIS; SMOOTH MUSCLE FIBER; THROMBOCYTOSIS;

ANIMALS; AORTA; BLOOD CELL COUNT; DRUG SYNERGISM; HYPERPLASIA; MALE; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; NUCLEAR PROTEINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINES; RATS; RATS, WISTAR; SIROLIMUS; TUNICA INTIMA; VON WILLEBRAND FACTOR;

EID: 55149083918     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000167272     Document Type: Article

References (36)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE;SIRIUS Investigators: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
2. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW: Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-678.
3. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L;SCAAR Study Group: Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
4. Laskey WK, Yancy CW, Maisel WH: Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006. Circulation 2007;115:2352-2357.
5. Gregory CR, Huie P, Billingham ME, Morris RE: Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 1993;55:1409-1418.
6. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhofer D, Schuhlen H, Goos C, Pache J, Dotzer F, Pogatsa-Murray G, Dirschinger J, Heemann U, Schomig A;OSIRIS Investigators: Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004;110:790-795.
7. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, Vigo CF, Delgado J, Fernandez-Pereira C, Pocovi A, Rodriguez-Granillo AM, Schulz D, Raizner AE, Palacios I, O'Neill W, Kaluza GL, Stone G;ORAR II Investigators: Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 2006;47:1522-1529.
8. Waksman R, Ajani AE, Pichard AD, Torguson R, Pinnow E, Canos D, Satler LF, Kent KM, Kuchulakanti P, Pappas C, Gambone L, Weissman N, Abbott MC, Lindsay J: Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 2004;44:1386-1392.
9. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-154.
10. Myllarniemi M, Frösen J, Calderon-Ramirez L, Buchdunger E, Lemström K, Häyry P: Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc Drugs Ther 1999;13:159-168.
11. Wang CH, Anderson N, Li SH, Szmitko PE, Cherng WJ, Fedak PW, Fazel S, Li RK, Yau TM, Weisel RD, Stanford WL, Verma S: Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. Circ Res 2006;99:617-625.
12. Sihvola R, Koskinen P, Myllarniemi M, Loubtchenkov M, Hayry P, Buchdunger E, Lemström K: Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Circulation 1999;99:2295-2301.
13. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME: Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:935-942.
14. Vamvakopoulos JE, Petrov L, Aavik S, Lehti S, Aavik E, Hayry P: Synergistic suppression of rat neointimal hyperplasia by rapamycin and imatinib mesylate: implications for the prevention of accelerated arteriosclerosis. J Vasc Res 2006;43:184-192.
15. Myllarniemi M, Calderon L, Lemstrom K, Buchdunger E, Hayry P: Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J 1997;11:1119-1126.
16. Aavik E, Luoto NM, Petrov L, Aavik S, Patel YC, Hayry P: Elimination of vascular fibrointimal hyperplasia by somatostatin receptor 1.4 selective agonist. FASEB J 2002;16:724-726.
17. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM: High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000;18:457-459.
18. Wang X, Seed B: A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003;31:e154.
19. Owens GK, Kumar MS, Wamhoff BR: Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004;84:767-801.
20. Ross R: Mechanisms of disease: atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
21. Sata M, Saiura A, Kunisato A, Tojo A, Okada A, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002;8:403-409.
22. Aavik E, Mahapatra A, Boldrick J, Chen X, Barry C, Dutoit D, Sarwal M, Häyry P: Correlation between gene expression and morphological alterations in baboon carotid after balloon dilatation injury. FASEB J 2005;19:130-132.
23. Leppanen O, Janjic N, Carlsson MA, Pietras K, Levin M, Vargeese C, Green LS, Bergqvist D, Ostman A, Heldin CH: Intimal hyperplasia recurs after removal of PDGF-AB and - BB inhibition in the rat carotid artery injury model. Arterioscler Thromb Vasc Biol 2000;20:E89-E95.
24. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R: Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004;63:617-624.
25. Du Toit D, Aavik E, Taskinen E, Myburgh E, Aaltola E, Aimonen M, Aavik S, van Wyk J, Hayry P: Structure of carotid artery in baboon and rat and differences in their response to endothelial denudation angioplasty. Ann Med 2001;33:63-78.
26. Shanahan CM, Weissberg PL, Metcalfe JC: Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Circ Res 1993;73:193-204.
27. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL: High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994;93:2393-2402.
28. Zhang CL, Kim S, Helmke BP, Yu WW, Du KL, Lu MM, Strobeck M, Yu QC, Parmacek MS: Analysis of SM22α-deficient mice reveals unanticipated insights into smooth muscle cell differentiation and function. Mol Cell Biol 2001;21:1336-1344.
29. Thyberg J, Hedin U, Sjolund M, Palmberg L, Bottger BA: Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 1990;10:966-990.
30. Louis HA, Pino JD, Schmeichel KL, Pomies P, Beckerle MC: Comparison of three members of the cysteine-rich protein family reveals functional conservation and divergent patterns of gene expression. J Biol Chem 1997;272:27484-27491.
31. Wei J, Gorman TE, Liu X, Ith B, Tseng A, Chen Z, Simon DI, Layne MD, Yet SF: Increased neointima formation in cysteine-rich protein 2-deficient mice in response to vascular injury. Circ Res 2005;97:1323-1331.
32. Dandre F, Owens GK: Platelet-derived growth factor-BB and Ets-1 transcription factor negatively regulate transcription of multiple smooth muscle cell differentiation marker genes. Am J Physiol Heart Circ Physiol 2004;286:H2042-H2051.
33. Liu Y, Sinha S, McDonald OG, Shang Y, Hoofnagle MH, Owens GK: Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression. J Biol Chem 2005;280:9719-9727.
34. Muto A, Fitzgerald TN, Pimiento JM, Maloney SP, Teso D, Paszkowiak JJ, Westvik TS, Kudo FA, Nishibe T, Dardik A: Smooth muscle cell signal transduction: implications of vascular biology for vascular surgeons. J Vasc Surg 2007;45:A15-A24.
35. Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Manganaro T, Donahoe PK: The immunophilin FKBP12 functions as a common inhibitor of the TGFβ family type I receptors. Cell 1996;86:435.
36. Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, Song YH, Titterington J, Delafontaine P: IGF-1 reduces inflammatory responses, suppresses oxidative stress and decreases atherosclerosis progression in Apoe-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:2684-2690.